NULISA NeuroData Commons
in partnership with GNPC

gnpc

OVERVIEW

Identifying the biological mechanisms driving neurodegenerative diseases, including Alzheimer's Disease , Parkinson's Disease , ALS, and Frontotemporal Dementia remains a critical barrier to the development of effective diagnostics and therapies. While the Global Neurodegeneration Proteomics Consortium (GNPC) established the value of large-scale harmonized proteomics via release of its v1 dataset in mid-2025, Alamar Biosciences' NULISA platform now enables a next phase of growth via a sensitive, scalable, and standardized targeted assay across many additional cohorts.

Launched in 2025, the NULISA NeuroData Commons applies a single next-generation assay platform across global neurodegenerative disease cohorts, profiling >40,000 new samples from longitudinal studies, genetic cohorts, and clinical trials. The NULISA CNS panel serves as the common baseline, enabling cross-cohort comparability and large-scale aggregation. All data will be processed through the AD Workbench, a secure and standardized environment, with a unified high-density dataset available to consortium members, followed by broader community access after a 6-month embargo.

Bringing together academic, governmental, clinical, and industry partners, the NULISA NeuroData Commons is built for scale with strong privacy protections, global data-sharing compliance, and infrastructure designed to accelerate biomarker discovery across the neurodegenerative landscape.

Please contact the NULISA NeuroData Commons for information on how to join the consortium via participation in novel biosample and/or dataset contribution, or via data analysis to help create collective progress on the diagnosis and treatment of these diseases.

Harmonized GNPC v1 dataset

GNPC v1 published articles

CORE PARTNERS AND FUNDERS

Alzheimer's Disease Data Initiative

gnpc Global Neurodegeneration Proteomics Consortium

Gates Ventures

~43K SAMPLES

- 3K FTD
- 1K PD
- 1K ALS
- 31K AD
- 6K Controls

MEMBERS

ace alzheimer center BARCELONA · ACTC ALZHEIMER'S CLINICAL TRIALS CONSORTIUM · ADNI · A·D·R·C for healthy brain aging · THE AGA KHAN UNIVERSITY

aibl · ALLFTD · ALS INSTITUTE · ANSWER ALS · Banner Health

barcelonaβeta BRAIN RESEARCH CENTER · Barcelona Brain Health Initiative · CHARIOT PRO · Davos Alzheimer's Collaborative · UNIVERSITÄT TÜBINGEN

EMORY UNIVERSITY Goizueta Alzheimer's Disease Research Center · BRAIN HEALTH INSTITUTE · GLOBAL ALZHEIMER'S PLATFORM FOUNDATION · JOHNS HOPKINS BIOCARD STUDY · KBASE

Keck School of Medicine of USC Alzheimer's Therapeutic Research Institute · KU ALZHEIMER'S DISEASE RESEARCH CENTER · LASI-DAD · LUNDS UNIVERSITET · NAGOYA UNIVERSITY · 1946 National Survey of Health and Development

MAYO CLINIC · THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH · Parkinson's Progression Markers Initiative · PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE · ReD-Lat Multi-Partner Consortium to Expand Dementia Research in Latin America

IU SCHOOL OF MEDICINE INDIANA ALZHEIMER'S DISEASE RESEARCH CENTER · Tracking Parkinson's · Tulane University · UCL · UK Dementia Research Institute

UCSF University of California San Francisco advancing health worldwide · UNIVERSITY OF GOTHENBURG · USF UNIVERSITY OF SOUTH FLORIDA · Washington University in St.Louis

DATA PLATFORM

Alzheimer's Disease Data Initiative

PROGRAM PARTNERS

ALAMAR BIOSCIENCES · Banner Health · UNIVERSITY OF GOTHENBURG · NMAS The difference is in the data.

MORE INFORMATION

info@neuroproteome.org